The takeaway
United Therapeutics Corporation shows a pronounced seasonal pattern over 10 years of data — strongest in October (+4.8%) and softest in March (−4.2%).
Right now
In July, the stock has risen 30% of years, averaging +0.2%, roughly 2.0 pts behind the S&P 500.
The full picture
United Therapeutics Corporation's most dependable month has been October, higher in 8 of 10 years; March has been its least reliable, up just 10% of the time.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Win rate % | ||||||||||||
| Median return % | ||||||||||||
| 2025 | ||||||||||||
| 2024 | ||||||||||||
| 2023 | ||||||||||||
| 2022 | ||||||||||||
| 2021 | ||||||||||||
| 2020 | ||||||||||||
| 2019 | ||||||||||||
| 2018 | ||||||||||||
| 2017 | ||||||||||||
| 2016 |
Month by month
The stock's clearest edge over the S&P 500 lands in October (+3.8 pts); it has trailed the market most in March (−5.2 pts).
“vs S&P” is United Therapeutics Corporation’s average for a month minus the S&P 500’s average for that same month — isolating United Therapeutics Corporation’s own seasonal edge from broad market drift.
Reality check
Over the last 5 years, October has closed higher 100% of the time versus 80% across the last 10 years — the pattern is strengthening.
Figures are the typical (median) October return and how often it rose — the last 5 years versus the last 10(the heatmap’s default window). This verdict stays anchored to that 10-year window even if you zoom the chart, so it never disagrees with the badges above.
In plain English
Strip the year back and a single month does the heavy lifting: October, up in 8 of 10 Octobers while the other eleven tend to blur together.
The headline flatters a touch — its +4.8% average sits well above the +2.1% a typical year delivers, the work of a few big Octobers. That reliability comes with real swings, mind — even October ranges by 10.7% from year to year, so any single year can land far from the average. Crucially, the gain is the stock's own rather than a rising tide's: October has cleared the S&P 500 by +3.8 points above the index. That consistency sets it apart from the field, where the average stock manages October only about 53% of the time.
The strength clusters rather than stands alone — October–December forms a firm stretch that carries much of the year. On the other side of the ledger, March has been the soft spot — the weakest of 4 months that average a loss (−4.2%), and the edge isn't year-round — the stock has trailed the S&P 500 in March, February, and September. Its roughest month on record was a −20.8% January in 2016 — a reminder of how hard even a seasonal name can fall.
October has now closed higher 7 years running. If anything it has sharpened recently — the last five Octobers run ahead of the earlier years.
The takeaway is less about when to buy than what to expect: October aside, the stock's months offer little reliable tilt.
Short answers on the stock's best month (October), its worst (March), and whether it really trades seasonally.
Yes, to a pronounced degree. Since 2016 its best month (October, +4.8%) has run well ahead of its worst (March, −4.2%) — the heatmap above shows how steady that gap has been year to year.
October has been the strongest, averaging +4.8% and closing higher in 8 of 10 years since 2016.
It's the weakest, averaging −4.2% — historically a soft spot, though it still varies from year to year.
Explore
These names have the strongest July track records on record — a starting point for comparison.
Before you trade